



Andrew Rezvani, M.D.

Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Medicine - Blood & Marrow Transplantation

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic F

MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-8950

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Janice Smith - Administrative Associate

Email janices1@stanford.edu

Tel (650) 724-4155

Bio

BIO

Dr. Rezvani is an Assistant Professor of Medicine in the Division of Blood & Marrow Transplantation and medical director of the inpatient blood and marrow transplant unit at Stanford University. As a clinician, he cares for people undergoing allogeneic and autologous hematopoietic cell transplantation. His research interests include optimizing the use of alternative donors for people who lack traditional fully-matched donors; the prevention and treatment of graft-vs.-host disease; the role of the microbiome in hematopoietic cell transplantation; and quality-of-care and systems improvement. He also teaches and serves as a research mentor for trainees in the Division of Blood & Marrow Transplant at Stanford.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Inpatient Medical Director, Blood & Marrow Transplant Unit, Stanford University, (2017- present)
- Cord Blood and Unrelated-Donor Director, Stanford University, Division of Blood & Marrow Transplantation, (2018- present)

HONORS AND AWARDS

- Member, Alpha Omega Alpha medical honor society (2001)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Cord Blood Advisory Group, National Marrow Donor Program (2019 - present)
- Member, Protocol Development Committee, Protocol 1703, Blood & Marrow Transplant Clinical Trials Network (BMT-CTN) (2017 - present)

- Member, Conflict of Interest Committee, Blood & Marrow Transplant Clinical Trials Network (BMT-CTN) (2018 - present)
- Member, Toxicity and Supportive Care Committee, Blood & Marrow Transplant Clinical Trials Network (BMT-CTN) (2015 - 2018)
- Editorial consultant, American College of Physicians PIER (2008 - 2016)

PROFESSIONAL EDUCATION

- Fellowship, Fred Hutchinson Cancer Research Center/University of Washington , Medical Oncology (2008)
- Residency, Duke University Medical Center , Internal Medicine (2004)
- M.D., Temple University , Medicine (2001)
- B.A., Stanford University , Slavic Languages and Literature (1997)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical research in allogeneic hematopoietic cell transplantation

CLINICAL TRIALS

- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Recruiting
- Axicabtagene Ciloleucef Expanded Access Study, Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Recruiting
- Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant, Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors, Recruiting
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Not Recruiting
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Efficacy of Axicabtagene Ciloleucef Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Expanded Access Protocol for Tabelecleucef for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting
- Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant, Not Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Not Recruiting
- MAGE A10#####T for Advanced NSCLC, Not Recruiting
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS), Not Recruiting

- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease, Not Recruiting
- TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801), Not Recruiting

Publications

PUBLICATIONS

- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
2019; 4 (10)
- **Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.** *Journal of hematology & oncology*
Epperla, N., Ahn, K. W., Litovich, C., Ahmed, S., Battiwalla, M., Cohen, J. B., Dahi, P., Farhadfar, N., Farooq, U., Freytes, C. O., Ghosh, N., Haverkos, B., Herrera, et al
2019; 12 (1): 6
- **Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Aronson, J. R., Rezvani, A. R., Subramanian, A.
2019
- **Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Singhal, S., Kim, T., Jenkins, P., Bassett, B., Tierney, D. K., Rezvani, A. R.
2019
- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
2019; 3 (16): 2454–64
- **Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.** *Blood advances*
Multani, A., Allard, L. S., Wangjam, T., Sica, R. A., Epstein, D. J., Rezvani, A. R., Ho, D. Y.
2019; 3 (22): 3602–12
- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2018
- **Elevated Axicabtagene Ciloleuce (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
AMER SOC HEMATOLOGY.2018
- **Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Casulo, C., Friedberg, J. W., Ahn, K. W., Flowers, C., DiGilio, A., Smith, S. M., Ahmed, S., Inwards, D., Aljurf, M., Chen, A., Choe, H., Cohen, J., Copelan, et al
2018; 24 (6): 1163–71
- **Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis** *BLOOD ADVANCES*
Shah, N. N., Ahn, K., Litovich, C., Fenske, T. S., Ahmed, S., Battiwalla, M., Bejanyan, N., Dahi, P. B., Bolanos-Meade, J., Chen, A. I., Ciurea, S. O., Bachanova, V., DeFilipp, et al
2018; 2 (8): 933–40
- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
2018; 2 (6): 681–90

- **Viral Isolates in the Cerebrospinal Fluid of Hematopoietic Stem Cell Transplant Recipients, 2007-2015**
Andermann, T., Asimwe, E., Buckley, M., Tkachenko, E., Greene, C., Rezvani, A., Bhatt, A. S.
ELSEVIER SCIENCE INC.2018: S378–S379
- **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**
Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffly, et al
ELSEVIER SCIENCE INC.2018: S145
- **Acute Graft-versus-Host Disease** *NEW ENGLAND JOURNAL OF MEDICINE*
Rezvani, A. R.
2018; 378 (6): 585–86
- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
2017; 23 (10): 1744–48
- **Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States** *BLOOD*
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., Battiwalla, M., Beitinjaneh, A., Cahn, et al
2017; 130 (9): 1156–64
- **Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.** *Cancer*
Weisdorf, D. J., Millard, H. R., Horowitz, M. M., Hyare, P. S., Champlin, R., Ho, V., Mielcarek, M., Rezvani, A., Stockerl-Goldstein, K., Khoury, H. J., de Lima, M., Saber, W., Sandmaier, et al
2017
- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
2017; 1 (17): 1347–57
- **Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.** *Journal of hematology & oncology*
Epperla, N., Ahn, K. W., Ahmed, S., Jagasia, M., DiGilio, A., Devine, S. M., Jaglowski, S., Kennedy, V., Rezvani, A. R., Smith, S. M., Sureda, A., Fenske, T. S., Kharfan-Dabaja, et al
2017; 10 (1): 117
- **Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors**
Spinner, M. A., Vina, M., Elder, L., Arai, S., Johnston, L., Meyer, E., Miklos, D., Muffly, L., Negrin, R. S., Shizuru, J., Weng, W., Laport, G. G., Strober, et al
AMER SOC HEMATOLOGY.2016
- **Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation**
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
AMER SOC HEMATOLOGY.2016
- **Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.** *Blood*
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., Brown, J. R., Dyer, M. J., Mato, A. R., Keating, M. J., Jaglowski, S., Clow, F., Rezvani, et al
2016
- **A new standard for HIV-associated lymphoma.** *Blood*
Rezvani, A. R.
2016; 128 (8): 1026-1027
- **Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.**
Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L. S., Negrin, R., Rezvani, A. R., Shizuru, J., Weng, W., Johnston, L. J.
AMER SOC CLINICAL ONCOLOGY.2016

- **Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.**
Neppalli, A., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W., Negrin, R., Meyer, E., Laport, G., Lowsky, R., Arai, S., Miklos, D., Rezvani, A. R.
AMER SOC CLINICAL ONCOLOGY.2016
- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al
ELSEVIER SCIENCE INC.2016: S204–S205
- **Immune Characterization of Ibrutinib Therapy Following Alloht That Provides GVL Benefit without Gvhd**
Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., Lowsky, R., Negrin, R., Miklos, D. B.
ELSEVIER SCIENCE INC.2016: S412
- **Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors** *BLOOD*
Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., Ahn, K. W., DiGilio, A., Beitinjaneh, A., Chhabra, S., Fenske, T. S., Freytes, C., Gale, R. P., Ganguly, S., Hertzberg, M., Klyuchnikov, et al
2016; 127 (7): 938-947
- **Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation** *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*
Andermann, T. M., Rezvani, A., Bhatt, A. S.
2016; 11 (1): 19-28
- **Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation.** *Current hematologic malignancy reports*
Andermann, T. M., Rezvani, A., Bhatt, A. S.
2016
- **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al
AMER SOC HEMATOLOGY.2015
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis**
Logan, A. C., Herrera, A. F., Ryan, C. E., Rezvani, A. R., Kong, K. A., Faham, M., Alatrash, G., Molldrem, J. J., Sargent, R. L., Alyea, E. P., Ho, V. T., Brown, J. R., Ritz, et al
AMER SOC HEMATOLOGY.2015
- **Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.** *Cancer*
Vaughn, J. E., Sorror, M. L., Storer, B. E., Chauncey, T. R., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., Hari, P., Laport, G. G., Franke, G. N., Agura, E. D., Langston, A. A., Rezvani, et al
2015; 121 (20): 3709-3716
- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al
2015; 50 (10): 1286-1292
- **Long-term outcomes of patients with persistent indolent b cell malignancies undergoing nonmyeloablative allogeneic transplantation.** *Biology of blood and marrow transplantation*
Cassaday, R. D., Storer, B. E., Sorror, M. L., Sandmaier, B. M., Guthrie, K. A., Maloney, D. G., Rajendran, J. G., Pagel, J. M., Flowers, M. E., Green, D. J., Rezvani, A. R., Storb, R. F., Press, et al
2015; 21 (2): 281-287

- **Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning**
Vaughn, J., Sorror, M. L., Chauncey, T., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., Hari, P. N., Laport, G. G., Franke, G., Agura, E., Langston, A., Rezvani, A., Stor, et al
ELSEVIER SCIENCE INC.2015: S88–S89
- **Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation**
Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., Otani, J., Kong, K. A., Klinger, M., Faham, M., Coutre, S., Miklos, D. B.
ELSEVIER SCIENCE INC.2015: S307–S308
- **Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.** *Biology of blood and marrow transplantation*
Rezvani, A. R., Storer, B. E., Guthrie, K. A., Schoch, H. G., Maloney, D. G., Sandmaier, B. M., Storb, R.
2015; 21 (1): 105-112
- **Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation**
Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., Otani, J., Kong, K. A., Klinger, M., Faham, M., Coutre, S., Miklos, D. B.
AMER SOC HEMATOLOGY.2014
- **Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes** *CURRENT OPINION IN HEMATOLOGY*
Rezvani, A. R., Sandmaier, B. M.
2013; 20 (6): 509-514
- **Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.** *Transplantation*
Sato, M., Storb, R., Loretz, C., Stone, D., Mielcarek, M., Sale, G. E., Rezvani, A. R., Graves, S. S.
2013; 96 (1): 34-41
- **Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, A. R., McCune, J. S., Storer, B. E., Batchelder, A., Kida, A., Deeg, H. J., McDonald, G. B.
2013; 19 (7): 1033-1039
- **Prevention of graft-vs.-host disease** *EXPERT OPINION ON PHARMACOTHERAPY*
Rezvani, A. R., Storb, R. F.
2012; 13 (12): 1737-1750
- **The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation** *BLOOD*
Scott, B. L., Gooley, T. A., Sorror, M. L., Rezvani, A. R., Linenberger, M. L., Grim, J., Sandmaier, B. M., Myerson, D., Chauncey, T. R., Storb, R., Buxhofer-Ausch, V., Radich, J. P., Appelbaum, et al
2012; 119 (11): 2657-2664
- **Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Yeh, R. F., Pawlikowski, M. A., Blough, D. K., McDonald, G. B., O'Donnell, P. V., Rezvani, A., Deeg, H. J., McCune, J. S.
2012; 18 (2): 265-272
- **Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Rezvani, A. R., Storer, B. E., Storb, R. F., Mielcarek, M., Maloney, D. G., Sandmaier, B. M., Martin, P. J., McDonald, G. B.
2011; 17 (11): 1594-1601
- **Rituximab resistance** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Rezvani, A. R., Maloney, D. G.
2011; 24 (2): 203-216
- **Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors.**
Sorror, M. L., Storer, B., Sandmaier, B. M., Franke, G. N., Laport, G. G., Chauncey, T., Agura, E., Maris, M. T., Wade, J., Pulsipher, M. A., Maziarz, R. T., Sahebi, F., McSweeney, et al
AMER SOC HEMATOLOGY.2010: 553

- **Allogeneic hematopoietic cell transplantation: the state of the art** *EXPERT REVIEW OF HEMATOLOGY*
Gyurkocza, B., Rezvani, A., Storb, R. F.
2010; 3 (3): 285-299
- **Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Flowers, M. E., Storer, B., Carpenter, P., Rezvoni, A. R., Vigorito, A. C., Campregher, P. V., Moravec, C., Kiem, H., Fero, M., Georges, G., Warren, E., Lee, S., Sanders, et al
2008; 14 (12): 1380-1384
- **Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience** *7th International Meeting on AAA Proteins*
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., Agura, E., Chauncey, T., Maziarz, R. T., Maris, M., Shizuru, J., Bruno, B., Bredeson, et al
WILEY-BLACKWELL PUBLISHING, INC.2008: 395-403
- **Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation** *Center of Excellence Meeting*
Rezvani, A. R., Storb, R. F.
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD.2008: 172-79
- **Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Rezvani, A. R., Storb, R.
2008; 8 (2): 161-179
- **Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma** *48th Annual Meeting of the American-Society-of-Hematology*
Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., Wade, J. C., Chauncey, T., Forman, S. J., Lange, T., Shizuru, J., Langston, A., Pulsipher, et al
AMER SOC CLINICAL ONCOLOGY.2008: 211-17
- **Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL)** *49th Annual Meeting of the American-Society-of-Hematology*
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Forman, S. J., Agura, E., Chauncey, T., Maziarz, R. T., Maris, M., Shizuru, J., Bruno, B., Wade, J. C., Lange, et al
AMER SOC HEMATOLOGY.2007: 892A-892A